| Autor: |
Keiran S.M. Smalley, Hussein Tawbi, Darrin Stuart, Geoffrey T. Gibney, Sarah Sloot, Friedegund Meier, John M. Kirkwood, Uma N. Rao, Alejandro Villagra, Elena B. Pasquale, Jane L. Messina, Vernon K. Sondak, Keith T. Flaherty, Hensin Tsao, Jobin K. John, Inna V. Fedorenko, John M. Koomen, Bin Fang, Meghna Das Thakur, Kim H.T. Paraiso |
| Rok vydání: |
2023 |
| DOI: |
10.1158/2159-8290.22530725 |
| Popis: |
Supplemental Figure 1. Characterization of the resistant cell lines. Supplemental Figure 2. Quantification of the cell invasion from figure 1D. Supplemental Figure 3. Model showing ligand dependent and independent ephrin signaling. Supplemental Figure 4. Acute drug treatment does not induce ligand independent ephrin signaling. Supplemental Figure 5. Quantification of matrigel invasion data from Figure 2E. Supplemental Figure 6. knockdown of EphA2 does not resensitize to BRAF inhibition. Supplemental Figure 7. PI3K and AKT inhibitors block AKT signaling. Supplemental Figure 8. Removal of drug increases cell doubling time. Supplemental Figure 9. Removal of drug reverses the resistance phenotype. Supplemental Figure 10. Removal of drug reverses EphA2 signaling and melanoma invasion. Supplemental Figure 11. Time course of EphA2 induction following chronic BRAF inhibition Supplemental Table 1. Levels of EphA2 staining in primary and metastatic melanoma lesions Supplemental Table 2. Increased EphA2 staining observed in melanoma patient specimens on BRAF inhibitor trial Supplemental Table 3. Incidence of new metastases in patients treated with either vemurafenib or dacarbazine. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
